- Home
- GERN vs CENT Comparison
GERN vs CENT Comparison
Compare GERN & CENT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- CENT
- Stock Information
- Founded
- GERN 1990
- CENT 1955
- Country
- GERN United States
- CENT United States
- Employees
- GERN N/A
- CENT N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- CENT Consumer Specialties
- Sector
- GERN Health Care
- CENT Consumer Discretionary
- Exchange
- GERN Nasdaq
- CENT Nasdaq
- Market Cap
- GERN 2.5B
- CENT 2.5B
- IPO Year
- GERN 1996
- CENT N/A
- Fundamental
- Price
- GERN $3.34
- CENT $39.43
- Analyst Decision
- GERN Strong Buy
- CENT Strong Buy
- Analyst Count
- GERN 10
- CENT 3
- Target Price
- GERN $7.05
- CENT $45.00
- AVG Volume (30 Days)
- GERN 8.0M
- CENT 165.5K
- Earning Date
- GERN 11-07-2024
- CENT 02-05-2025
- Dividend Yield
- GERN N/A
- CENT N/A
- EPS Growth
- GERN N/A
- CENT N/A
- EPS
- GERN N/A
- CENT 1.62
- Revenue
- GERN $29,480,000.00
- CENT $3,200,460,000.00
- Revenue This Year
- GERN $32,021.10
- CENT $2.67
- Revenue Next Year
- GERN $298.14
- CENT $2.19
- P/E Ratio
- GERN N/A
- CENT $24.34
- Revenue Growth
- GERN 9199.68
- CENT N/A
- 52 Week Low
- GERN $1.64
- CENT $32.17
- 52 Week High
- GERN $5.34
- CENT $47.48
- Technical
- Relative Strength Index (RSI)
- GERN 25.88
- CENT 48.91
- Support Level
- GERN $3.75
- CENT $38.84
- Resistance Level
- GERN $4.00
- CENT $43.88
- Average True Range (ATR)
- GERN 0.17
- CENT 1.31
- MACD
- GERN -0.06
- CENT -0.33
- Stochastic Oscillator
- GERN 7.41
- CENT 11.71
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About CENT Central Garden & Pet Company
Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.